Thyroid hormone receptor-b1 (TRb1) belongs to the ligand-inducible transcription factor superfamily. We have previously described that stable TRb1 expression impairs fibroblast proliferation diminishing levels and activity of the main regulators of the G 1 /S transition. To unmask the underlying molecular mechanism of this action, we have investigated the expression of cyclin D1, E and A2 upon serum stimulation in TRb1 expressing cells, finding a strong downregulation of their mRNAs, concomitant with low protein levels. The inhibition of the transcriptional activation in response to serum of these cyclins is differently exerted. For cyclin D1, we demonstrate that TRb1 represses its promoter as a consequence of the downregulation of c-jun levels, diminished AP-1 activation and loss of c-jun recruitment to its binding sites on cyclin D1 promoter. For cyclin E and A2, it is the impairment of the cyclinD/Rb/E2F pathway by TRb1 that prevents the activation of these two E2F target genes. Indeed, recruitment of E2F-1 to cyclin A2 promoter could not be detected. In summary, we propose that apo-TRb1 exerts its antiproliferative action through a mechanism that could constitute a model by which other nuclear receptors may control cell division.
Thyroid hormone receptor-b1 (TRb1) belongs to the ligand-inducible transcription factor superfamily. We have previously described that stable TRb1 expression impairs fibroblast proliferation diminishing levels and activity of the main regulators of the G 1 /S transition. To unmask the underlying molecular mechanism of this action, we have investigated the expression of cyclin D1, E and A2 upon serum stimulation in TRb1 expressing cells, finding a strong downregulation of their mRNAs, concomitant with low protein levels. The inhibition of the transcriptional activation in response to serum of these cyclins is differently exerted. For cyclin D1, we demonstrate that TRb1 represses its promoter as a consequence of the downregulation of c-jun levels, diminished AP-1 activation and loss of c-jun recruitment to its binding sites on cyclin D1 promoter. For cyclin E and A2, it is the impairment of the cyclinD/Rb/E2F pathway by TRb1 that prevents the activation of these two E2F target genes. Indeed, recruitment of E2F-1 to cyclin A2 promoter could not be detected. In summary, we propose that apo-TRb1 exerts its antiproliferative action through a mechanism that could constitute a model by which other nuclear receptors may control cell division. Oncogene (2008 Oncogene ( ) 27, 2795 Oncogene ( -2800 doi:10.1038/sj.onc.1210936; published online 26 November 2007 Keywords: thyroid hormone receptor; cyclins; E2F-1; AP-1; nuclear receptors; cell cycle Thyroid hormone nuclear receptors (TRs) belong to the superfamily of ligand-inducible transcription factors. Two genes, Thra and Thrb, encode the major bona fide receptors TRa1 and b1, and other non-thyroid hormone (TH)-binding and truncated variants, through transcription from different promoters and alternative splicing (Koenig et al., 1989; Chassande et al., 1997) . Each isoform displays specific spatio-temporal patterns of expression, and unique functions for TR variants are now emerging, overcoming the first idea of functional redundancy (O'Shea and Williams, 2002) . TH exerts its physiological actions regulating target gene expression through TRs (reviewed in Zhang and Lazar, 2000) . It is generally accepted that unliganded/apo-TRs and liganded/holo-TRs display antagonic actions on target gene transcription exchanging co-repressors for coactivators upon ligand binding (Glass and Rosenfeld, 2000) . Nuclear receptors can also regulate the expression of genes that do not contain hormone response elements by the mechanism generally referred to as 'transcriptional cross-talk' with other transcription factors or signalling pathways (Gottlicher et al., 1998) . Linking TRs and thyroid status to tumourigenesis, it has been reported that TH suppresses RAS-mediated transformation, alterations in TR expression in many human neoplasias and the presence of dominant-negative TR mutations in hepatocarcinomas (Gonzalez-Sancho et al., 2003; Garcia-Silva and Aranda, 2004; Chan and Privalsky, 2006) . Moreover, TRb physically interacts with cell cycle regulators as cyclin D1 and p53 (Yap et al., 1996; Bhat et al., 1997; Barrera-Hernandez et al., 1998; Lin et al., 2002) and we have previously reported a specific role for apo-TRb in cell cycle control (Porlan et al., 2004) . As demonstrated therein, TRb1 and not TRa exerts its antiproliferative actions by loss of the timely activation of the signals that drive cell cycle progression resulting in a 10 h lengthening of the cell cycle that is independent of the presence of its ligand. Among other findings, we described the downregulation of G 1 -cyclins protein levels in cells expressing TRb1. To determine if this was a consequence of cyclin mRNA downregulation, we have performed real-time RT-PCRs in control (empty-vector infected) and TR8b (TRb1 infected, clone no. 8; see Porlan et al., 2004 ) Swiss 3T3 fibroblasts, either quiescent (G 0 ) or stimulated with THdepleted serum to force cell cycle re-entry. As shown (Figure 1a) , cyclin D1 mRNA increased eight-and twofold in control and TRb-expressing cells, respectively. However, cyclin D2 and D3 mRNA levels only increased twofold and similarly in both cell types, indicating that cyclin D1 is apparently the only D-type cyclin whose expression is affected by TRb1. Protein levels followed the same pattern of induction as the mRNA (Figure 1b ): cyclin D1 induction is impeded in TRb-expressing cells in contrast to control, where a dramatic increase can be observed in response to serum.
The increase in cyclin D2 protein in serum-induced control cells (middle panel, Figure 1b ) is probably due to the crossreactivity of the antibody used (sc-593) with cyclin D1 as confirmed by the low and similar cyclin D2 mRNA increase in both cell types. Finally, cyclin D3 protein levels displayed a similar increase in both types, as shown for the mRNA.
In spite of the lack of early induction of cyclin D1 in TRb-expressing cells after serum stimulation, the same level of this cyclin was finally reached in both cell types (Porlan et al., 2004) . Then, we extended our analysis (performing parallel real-time RT-PCR and western blot experiments) at later time points. Indeed, we found that both cyclin D1 mRNA (at 16 h) and protein (at 20 h) levels were the same in both cells when the decline of control levels met the small induction produced in TRbexpressing cells (Figure 1c) .
Next, we examined the levels of cyclin E and A2 mRNAs by real-time RT-PCR upon serum stimulation at indicated time points (Figures 2a and b) . We found that both cyclin E and A2 reached maximum levels 8 h later (at 16 h) than the cyclin D1 did so (at 8 h). Interestingly, the increase in cyclin E mRNA was of B7-vs twofold in control and TRb-cells, respectively, at 8 h, but was the same (B12-fold) 16 h after serum exposure. Protein levels also accumulated following a delayed pattern in TRb cells, not reaching control levels until 20 h (Figure 2a ). In contrast, cyclin A2 expression Figure 1 (a) TRb1 expression inhibits the serum-dependent cyclin D1 expression stimulation. For all experiments, Swiss 3T3 control and TR8b cells were seeded at low density, grown to confluence and serum starved, and were either left quiescent (G 0 ) or stimulated with TH-depleted-serum containing medium for the times indicated as described (Porlan et al., 2004) , unless otherwise indicated. Total RNA was prepared using TRIzol reagent (Invitrogen, Paisley, UK) and reverse-transcribed with Superscript One Step RT-PCR Kit (Invitrogen). PCR products were amplified using primer sets specific for cyclin D1, D2, D3 and L32 transcripts, and analysed by real-time PCR using a Rotor Gene instrument (Corbett Research, Cambridge, UK) (PCR conditions and oligonucleotide sequences are available on demand). Quantitation of the products was based on SYBR Green fluorescence and referred to L32. Standardized data were subjected to the DD-Ct method (Pfaffl, 2001) and induction values were normalized to each G 0 value. Means ± s.e.m. (n ¼ 3). *Po0.05; All statistical analyses were performed using two-tailed unpaired Student's t-test unless stated otherwise. (b) D-cyclin protein levels in TRb cells. Immunoblots for cyclin D1, D2 and D3 were performed as described (Porlan et al., 2004) Inhibition of cyclins D1, E and A expression by TRb E Porlan et al augmented B20-fold in control cells at 16 h after serum exposure but only eightfold in TRb-expressing cells and remained under control levels at 20 h ( Figure 2b ). Likewise, induction of cyclin A2 protein in TRbexpressing cells was strongly reduced compared to control at all time-points studied. These data indicate that TRb is provoking a delay on the expression of cyclins D1, E and A2 impeding their timed accumulation and causing growth arrest. This TRb-mediated effect is independent of the presence of the ligand, since addition of 50 nM TH for 1 and 3 days to the medium did not modify the growing capabilities of the clones infected with TRb, as seen by 3 H-thymidine incorporation measurements in control and TRb-expressing fibroblasts (not shown).
In order to rule out a possible effect on messenger stability that could account for the differences observed in mRNA levels, we performed real-time RT-PCR in extracts from cells treated with the inhibitor of transcription actinomycin-D. The serum-induced cyclins mRNA increment is due to the transcription of the gene in early G 1 phase (Sherr, 1995; Krude et al., 1997) . Accordingly, cyclin D1, E and A2 mRNA increments found in our system were completely abrogated with actinomycin-D treatment in both cell types (Figure 2c) . Additionally, we determined cyclin D1, E and A2 mRNAs half-life in the presence of actinomycin-D for both cell types and found no significant differences in TRb-expressing vs control cells (data not shown). Thus, the low cyclin mRNA levels found in TRb cells are not due to changes in mRNA stability but to different rates of transcription. Hence, and given that TRb1 can regulate gene transcription in the absence of its ligand (Hashimoto et al., 2001) , we postulated that TRb1 could be interfering with the cell cycle machinery at the level of cyclins D1, E and A2 transcription.
To test this hypothesis, we performed transient transfection assays but using a related cellular model, NIH3T3 fibroblasts, that overcomes the low efficiency obtained with Swiss 3T3. Cells were transfected as described (Porlan et al., 2004) with an expression vector containing TRb1 fused to the green fluorescent protein and a reporter plasmid containing a cyclin D1 promoter fragment linked to the luciferase gene. Cells were either left unstimulated (G 0 ) or TH-depleted serum stimulated for 7 h, and luciferase activity was measured and normalized to the total protein present in the extracts. As shown (Figure 3a) , cyclin D1 promoter activity increased B3-fold upon serum stimulation whereas TRb1 inhibited this activation in more than 50%, reaching only B1.4-fold. These data directly implicate TRb1 in the control of cyclin D1 transcription in response to serum. Interestingly, cyclin D1 activation by oncogenic RAS is suppressed by TH (Garcia-Silva and Aranda, 2004) , which would suggest a cooperative effect between TH and apo-TRb1 in cyclin D1 repression. This is also the case for other nuclear receptors such as all-trans-retinoic acid receptors, which have been reported to repress an AP-1 responsive promoter independently of their ligand, whilst the addition of retinoic acid enhanced this effect (Benkoussa et al., 2002) .
Given that cyclin D1 promoter does not contain any TH-response elements, the observed repression must be presumably mediated by a mechanism of interference between TRb1 and one or more of the factors involved in its transcription. AP-1 transcription factor participates in the control of cellular responses to stimuli in the G 0 /G 1 transition driving the transcription of cyclin D1 (Shaulian and Karin, 2001) . Noteworthy, TRs among other nuclear receptors can act as ligand-dependent transrepressors of AP-1 activity (Pfahl, 1993) and it is Gel retardation assays were performed as described (Deogracias et al., 2004) in nuclear extracts from control and TRb cells. Oligonucleotides containing the consensus AP-1 sequence are 5 0 -TCGACATCTGCGTCAGCA GGTTTC-3 0 (s); 5 0 -TCGAGAAACCTGCTGACGCAGATG-3 0 (as). For competition analyses 100-fold molar excess of the specific AP-1 (C) or unspecific (NS) unlabelled oligonucleotides was added to the reaction mixture. (d) In vivo occupancy of cyclin D1 promoter. ChIP assays were performed as described elsewhere (Yamaguchi et al., 2005) using anti-c-jun (H-79, sc-1694X; Santa Cruz) antibody or rabbit immunoglobulin G (IgG). DNA fragments were phenol-extracted and analysed by semi-quantitative PCR using primers flanking the AP-1 site on the cyclin D1 promoter:
No template (NTC), no-antibody (IgG) controls and distal primers were used to verify the specificity of the analyses in all ChIP assays. One out of two independent experiments is shown.
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believed that many of the antiproliferative effects of nuclear receptor ligands could be mediated by their anti-AP-1 activity. AP-1 transcription factor is composed of jun family members that can form either homo-or hetero-dimers among themselves, and with members of fos and ATF/CREB families. C-jun and c-fos protein levels strongly increase shortly after serum exposure of quiescent mouse fibroblasts. Densitometric analyses of western blots from Swiss 3T3-control fibroblasts (Figure 3b) showed a c-jun 2.5-fold increase 1 h after serum addition, in contrast to TRb cells where c-jun slightly increased over basal levels at the time points studied. We found that this lack of induction was specific for c-jun, as analysis of c-fos protein showed no significant differences between control and TRb-cells. The importance of c-jun promoting cell proliferation has been stated in c-jun deficient mouse embryonic fibroblasts, which fail to activate cyclin D1, leading to an inefficient G 1 to S phase progression (Wisdom, 1999) . Given that AP-1 activity follows the kinetics of c-jun and c-fos protein accumulation and that the composition of AP-1 dimers reflects their respective abundance, we postulated that AP-1 transcription factor activity might be inhibited in TRb-expressing cells. This point was confirmed by gel retardation assays: as shown in Figure 3c , we found less active AP-1 complexes in nuclear extracts obtained from TRb cells compared with control, 4 h after serum stimulation. To investigate whether this lack of AP-1 activity resulted in reduced in vivo occupancy of cyclin D1 promoter, we performed chromatin immunoprecipitation (ChIP) experiments. Protein-DNA complexes were immunoprecipitated with an anti-c-jun antibody, and DNA fragments were recovered and subjected to semi-quantitative PCR with a set of oligonucleotides specific for the AP-1 binding region of the cyclin D1 promoter. Another set specific for a non-promoter region was included as a negative control. As shown (Figure 3d ), serum exposure provoked the recruitment of c-jun to cyclin D1 promoter in quiescent control fibroblasts, in contrast to TRbexpressing cells, where it could not be detected at this time point. Since some level of AP-1 activity was still present in TRb-expressing cells (Figure 3c ), we can assume that it would be bound to the cyclin D1 promoter, but to a level not detected in the ChIP assay. Hence, the functional outcome of the lack of c-jun induction seems to be a failure to timely recruit the active transcription factor AP-1 to cyclin D1 promoter, and diminished cyclin D1 transcription in response to serum. Additionally, the expression of a TRb1 dominant-negative mutant in vivo provokes cyclin D1 overexpression and pituitary tumours in mice (Furumoto et al., 2005) supporting the idea that cyclin D1 regulation is an important target of cell cycle control by TRb1.
Next, we hypothesized that cyclin E and A2 mRNAs downregulation might be due to the altered Rb/E2F pathway, in addition to or as a consequence of the lack of cyclin D1. Accordingly, we found that levels of E2F-1 protein in asynchronously growing Swiss 3T3 fibroblasts were markedly reduced in TRb-expressing cells. (Campanero et al., 2000) , and pEGFP-vector empty or containing wild-type TRb (TRb) or an AF-2 domain mutant lacking aminoacids 452-461 (DAF-2-TRb). Luciferase activity was normalized to b-galactosidase values. Results are fold increase over the mutE2F-reporter/ empty vector values; means ± s.e.m., (n ¼ 3). ***Po0.001 (vs wtE2F). (Right) Immunoblot with anti-GFP antibody (BDBiosciences, Erembodegen, Belgium) to verify the levels of the expressed fusion proteins. (d) Cyclin A2 promoter activation is repressed by TRb1. NIH3T3 cells lentivirally infected with TRb or empty vector were transfected with a reporter plasmid containing a fragment of the cyclin A2 promoter (Sanz-Gonzalez et al., 2004) . Luciferase activity was normalized to the total protein content in the extracts. Shown are results from one representative experiment out of three independent. Data are fold increase over the G 0 values; means±s.e.m., n ¼ 3; *Po0.05 (vs control). (e) Cyclin A2 promoter occupancy by E2F-1 in TRb expressing cells. ChIP assay using anti-E2F-1. Primers flank the E2F-1 site on cyclin A2 promoter: 5 0 -CCCGCCCTGTAAGATTCC-3 0 (s); 5 0 -CGGCTG CTGGTCTTGTAG-3 0 (as). Experiments were performed twice with similar results.
Densitometric analyses showed 40% less E2F-1 in TRb vs control cells (Figure 4a ). Interestingly, E2F-1 mRNA levels were higher in TRb-expressing cells (Figure 4b ), in agreement with the reported finding of a negative THresponse element in the E2F-1 promoter (Nygard et al., 2003) , which suggests an additional post-transcriptional regulation of this factor. Besides, we have previously demonstrated that transient TRb expression inhibits serum-induced E2F transcriptional activity (Porlan et al., 2004) . Expression of different TRb mutants showed that this effect required an intact DNA-binding domain but it was ligand-binding independent. Using a new mutant in which the AF-2 ligand-dependent transactivation domain has been deleted (DAF-2-TRb), we confirmed that the downregulation of E2F activity is independent of the TRb ligand-mediated transcriptional activity (Figure 4c ). The previous results, showing lower E2F-1 protein levels and reduced E2F-dependent transcriptional activity strongly suggest a reduced E2F-1 dependent activation of cyclin E and A2 promoters in TRb-expressing cells. Cyclin E is regulated by two E2F elements: a repressor one that vacates when the promoter activates, and a bipartite E2F-Sp1 site which binds E2F-1 constitutively during the cell cycle (Botz et al., 1996; Le Cam et al., 1999) . Thus, the study of the occupancy by E2F-1 of this promoter using ChIP assays does not yield definitive conclusions (results not shown). Given that in TRb-expressing cells cyclin E time-course of induction upon serum stimulation is only significant at 8 h and reached control levels thereafter, and the complexity of the E2F regulation of its promoter, we suggest that cyclin E is less affected by the reduction on E2F activity in contrast to cyclin A2.
Indeed, primers flanking E2F-1-binding sites of cyclin A2 promoter revealed the absence of E2F-1 recruitment to this promoter in TRb-expressing cells 16 h after serum addition, while occupancy was confirmed for control cells (as shown in Rayman et al., 2002) ( Figure 4e ). Moreover, activity of cyclin A2 promoter in TRb-expressing cells was clearly reduced (Figure 4d ). Our results indicate that the lack of transcriptional activation of cyclin A2 is downstream of the inhibition of cyclin D1 by TRb1 and related to the failure of E2F factors to activate transcription. In summary, we show that apo-TRb1 exerts its antiproliferative action through a mechanism that involves the transcriptional inhibition of cyclin D1, E and A2 in response to serum, due to the indirect repression of AP-1 and E2F-1 transcription factors. We propose that this could define a general mechanism by which other nuclear aporeceptors may control cell division, not only under physiological conditions but also in pathological situations such as cell transformation and cancer.
